モルグラモスチム市場：市場規模、予測、新たな洞察-2032年

モルグラモスチムネブライザー液（モルグラモスチム）は、遺伝子組換えヒト顆粒球マクロファージコロニー刺激因子（GM-CSF）の非グリコシル化製剤です。Savaraは、自己免疫性肺胞蛋白症（aPAP）の治療オプションとなり得る吸入製剤を開発しています。モルグラモスチムの吸入により肺胞のマクロファージが活性化されるため、肺胞マクロファージのサーファクタント除去活性が回復し、酸素化が大幅に改善される可能性があります。

今後数年間で、自己免疫性肺胞蛋白症（aPAP）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化することが予想されます。各社は、病態を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、モルグラモスチムの優位性に影響を与える可能性のある機会を模索しています。自己免疫性肺胞蛋白症（aPAP）に対する他の新興製品は、モルグラモスチムとの厳しい市場競争になると予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるモルグラモスチム市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 自己免疫性肺胞蛋白症（aPAP）におけるモルグラモスチムの概要

• 製品詳細
• 臨床開発
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 モルグラモスチム市場評価

• 自己免疫性肺胞蛋白症（aPAP）におけるモルグラモスチムの市場展望
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Molgramostim, Clinical Trial Description, 2023
• Table 2: Molgramostim, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Molgramostim Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Molgramostim Market Size in the US, in USD million (2019-2032)
• Table 7: Molgramostim Market Size in Germany, in USD million (2019-2032)
• Table 8: Molgramostim Market Size in France, in USD million (2019-2032)
• Table 9: Molgramostim Market Size in Italy, in USD million (2019-2032)
• Table 10: Molgramostim Market Size in Spain, in USD million (2019-2032)
• Table 11: Molgramostim Market Size in the UK, in USD million (2019-2032)
• Table 12: Molgramostim Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Molgramostim Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Molgramostim Market Size in the United States, USD million (2019-2032)
• Figure 3: Molgramostim Market Size in Germany, USD million (2019-2032)
• Figure 4: Molgramostim Market Size in France, USD million (2019-2032)
• Figure 5: Molgramostim Market Size in Italy, USD million (2019-2032)
• Figure 6: Molgramostim Market Size in Spain, USD million (2019-2032)
• Figure 7: Molgramostim Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Molgramostim Market Size in Japan, USD million (2019-2032)

"Molgramostim Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the seven major markets. A detailed picture of the Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP). The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Molgramostim market forecast analysis for Autoimmune pulmonary alveolar proteinosis (aPAP) in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Autoimmune pulmonary alveolar proteinosis (aPAP).

Drug Summary:

Molgramostim nebulizer solution (molgramostim) is a non-glycosylated form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Savara is developing an inhaled formulation as a potential treatment option for autoimmune pulmonary alveolar proteinosis (aPAP). The inhalation of molgramostim activates macrophages in the lung alveoli, thus potentially restoring the surfactant-clearing activity of the alveolar macrophages and considerably improving oxygenation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Molgramostim description, mechanism of action, dosage and administration, research and development activities in Autoimmune pulmonary alveolar proteinosis (aPAP).
• Elaborated details on Molgramostim regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Molgramostim research and development activities in Autoimmune pulmonary alveolar proteinosis (aPAP) across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Molgramostim.
• The report contains forecasted sales of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for autoimmune pulmonary alveolar proteinosis (aPAP).
• The report also features the SWOT analysis with analyst views for Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Molgramostim Analytical Perspective by DelveInsight

• In-depth Molgramostim Market Assessment

This report provides a detailed market assessment of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Molgramostim Clinical Assessment

The report provides the clinical trials information of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Autoimmune pulmonary alveolar proteinosis (aPAP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Molgramostim dominance.
• Other emerging products for Autoimmune pulmonary alveolar proteinosis (aPAP) are expected to give tough market competition to Molgramostim and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).
• Our in-depth analysis of the forecasted sales data of Molgramostim from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP).

Key Questions:

• What is the product type, route of administration and mechanism of action of Molgramostim?
• What is the clinical trial status of the study related to Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Molgramostim development?
• What are the key designations that have been granted to Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• What is the forecasted market scenario of Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• What are the forecasted sales of Molgramostim in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Molgramostim for Autoimmune pulmonary alveolar proteinosis (aPAP)?
• Which are the late-stage emerging therapies under development for the treatment of Autoimmune pulmonary alveolar proteinosis (aPAP)?

Table of Contents

1. Report Introduction

2. Molgramostim Overview in Autoimmune pulmonary alveolar proteinosis (aPAP)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Molgramostim Market Assessment

• 5.1. Market Outlook of Molgramostim in Autoimmune pulmonary alveolar proteinosis (aPAP)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Molgramostim in the 7MM for Autoimmune pulmonary alveolar proteinosis (aPAP)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Molgramostim in the United States for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.2. Market Size of Molgramostim in Germany for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.3. Market Size of Molgramostim in France for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.4. Market Size of Molgramostim in Italy for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.5. Market Size of Molgramostim in Spain for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.6. Market Size of Molgramostim in the United Kingdom for Autoimmune pulmonary alveolar proteinosis (aPAP)
  • 5.3.7. Market Size of Molgramostim in Japan for Autoimmune pulmonary alveolar proteinosis (aPAP)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options